
|Articles|July 1, 2004
Gene-directed therapy for AMD on the horizon
Iowa City, IA-The development of gene-directed therapy for common genetic ocular diseases that will be deployable on a population scale rests on coordinated research involving a series of steps. However, judging from progress made so far, such modalities might become clinically available soon, said Edwin M. Stone, MD, PhD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
What if? Ophthalmology without OCT – Part 1
2
AAO 2025: Ophthalmic World Leaders honors 2025 leadership awardees
3
ICYMI: AAO 2025 showcases new technologies and continued research
4
Q&A: William F. Wiley, MD, on what BVI's trifocal IOL approval means for US premium vision options
5

















































.png)


